Details of the Drug

General Information of Drug (ID: DMCBJSR)

Drug Name
Sunitinib
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Acute undifferentiated leukemia N.A. Approved [1]
Chronic myelomonocytic leukemia N.A. Approved [1]
Classic Kaposi sarcoma N.A. Approved [1]
Gastrointestinal cancer 2C11 Approved [2]
Gastrointestinal stromal tumour 2B5B Approved [3]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Lung cancer 2C25.0 Approved [1]
Mast cell leukaemia 2A21.00 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Pancreatic cancer 2C10 Approved [1]
Primary myelofibrosis 2A20.2 Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Prostate adenocarcinoma N.A. Approved [1]
Refractory chronic myeloid leukaemia 2A20 Approved [1]
Salivary gland squamous cell carcinoma N.A. Approved [1]
Plexiform neurofibroma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
ATC Code
L01EX01: Sunitinib
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 398.5
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The apparent oral clearance of drug is 34-62 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 40 - 60 hours [4]
Metabolism
The drug is metabolized via the cytochrome P450 enzyme CYP3A4 []
Vd
The volume of distribution (Vd) of drug is 2230 L []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Hypertension rs4646437 CYP3A4 OTQGYY83 [5]
Vomiting Not Available ABCG2 ABCP BCRP BCRP1 MXR OTW8V2V1 [6]
Chemical Identifiers
Formula
C22H27FN4O2
IUPAC Name
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Canonical SMILES
CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
InChI
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChIKey
WINHZLLDWRZWRT-ATVHPVEESA-N
Cross-matching ID
PubChem CID
5329102
ChEBI ID
CHEBI:38940
CAS Number
557795-19-4
TTD ID
D0R0MW
VARIDT ID
DR00454
INTEDE ID
DR1519
ACDINA ID
D00646
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Drug Response [6]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Drug Response [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute undifferentiated leukemia
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 2.27E-01 0.03 0.14
P-glycoprotein 1 (ABCB1) DTP P-GP 4.70E-06 -5.80E-02 -1.98E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 1.20E-13 -1.20E+00 -1.06E+00
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 4.93E-05 -5.25E-02 -3.14E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 9.49E-02 5.87E-03 5.86E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 1.69E-01 2.37E-02 2.14E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 7.29E-03 -3.47E-02 -1.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 208 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 1.4022 3.5666 1.3846 30.9856
JK1 CTRP2 1.7689 3.3393 1.7653 28.4961
JM1 GDSC1; CTRP2 2.3742 4.2832 2.3492 24.5352
EoL-1 GDSC1; CTRP2 -10.3542 -8.1739 -10.3542 98.5418
MOLM-13 GDSC1; CTRP2 -7.4556 -5.2385 -7.4557 88.5811
MV4-11 GDSC1; CTRP2 -7.2358 -4.071 -7.2361 85.9515
SEM CTRP2 -4.1249 2.309 -4.3012 64.9282
ALL-PO GDSC1 -4.0299 2.497 -4.5406 71.0357
Mono-Mac-6 GDSC1; CTRP2 -3.7024 6.587 -4.7456 59.8232
NKM-1 GDSC1 -3.2053 2.2747 -3.5886 67.6856
MOLM-16 CTRP2 -0.7851 3.0902 -0.857 45.6281
Mono-Mac-1 CTRP2 -0.3237 18.1994 -5.9088 46.8386
697 GDSC1; CTRP2 -0.2983 1.896 -0.3018 42.2666
Pfeiffer CTRP2 -0.1917 2.0341 -0.196 41.5591
MOLT-16 GDSC1; CTRP2 0.1744 1.6505 0.1742 39.1075
Kasumi-1 GDSC1; CTRP2 0.2087 1.937 0.2078 38.8813
OCI-AML-5 GDSC1; CTRP2 0.3925 1.5568 0.3925 37.6539
GA-10 GDSC1; CTRP2 0.4093 1.8982 0.409 37.543
Ki-JK CTRP2 0.4222 1.1577 0.4222 37.4558
NCI-H929 CTRP2 0.434 2.0935 0.4331 37.3803
KMS-11 CTRP2 0.542 4.3756 0.399 37.0941
OCI-AML-2 GDSC1; CTRP2 0.5432 2.5271 0.5391 36.6633
A4/Fukuda GDSC1; CTRP2 0.5887 3.3671 0.5553 36.454
ALL-SIL GDSC1; CTRP2 0.6163 2.4705 0.6136 36.1717
Karpas-299 GDSC1; CTRP2 0.74 3.412 0.7093 35.4388
KHM-1B CTRP2 0.7459 2.0688 0.7457 35.3
SIG-M5 GDSC1; CTRP2 0.7863 2.0176 0.7862 35.0306
CTV-1 GDSC1 0.7944 2.7134 0.6647 28.3962
JURL-MK1 CTRP2 0.8274 2.9854 0.8177 34.7884
A3/Kawakami GDSC1; CTRP2 0.8563 2.5606 0.8544 34.5701
DoHH2 GDSC1 0.8622 2.4568 0.7897 27.1841
OCI-Ly19 GDSC1; CTRP2 0.879 3.285 0.8596 34.4766
DEL GDSC1; CTRP2 0.9808 2.4068 0.9803 33.736
SR GDSC1; CTRP2 0.9985 2.552 0.9973 33.6204
NCO2 CTRP2 0.9999 2.3699 0.9995 33.6082
BL-41 GDSC1 1.0005 3.2909 0.732 26.7382
SU-DHL-1 GDSC1; CTRP2 1.0269 1.7081 1.0269 33.4272
Karpas-45 GDSC1 1.0912 2.6532 1.0003 24.445
H9 GDSC1 1.1326 4.9007 0.2499 28.9695
Karpas-231 GDSC1 1.1691 2.6561 1.0841 23.4331
RS4;11 GDSC1; CTRP2 1.178 4.1694 1.1038 32.6658
NALM-6 GDSC1; CTRP2 1.2313 3.8684 1.1885 32.2077
Ku812 GDSC1; CTRP2 1.2578 3.1731 1.2507 31.9126
CML-T1 CTRP2 1.2781 3.1813 1.271 31.7775
F-36P CTRP2 1.302 3.4238 1.2878 31.6419
RPMI-8402 GDSC1; CTRP2 1.3204 2.7807 1.3193 31.4755
WIL2 NS GDSC1 1.3414 3.0093 1.1874 21.7415
NK-92MI GDSC1 1.3465 3.3565 1.0869 22.3953
AML-193 CTRP2 1.3475 3.0756 1.3435 31.3046
SU-DHL-16 GDSC1 1.3603 2.3745 1.3346 20.6594
NU-DUL-1 GDSC1; CTRP2 1.3852 2.7646 1.3844 31.0427
ML-2 GDSC1 1.3952 4.9807 0.4838 26.14
KE-97 CTRP2 1.4226 4.0356 1.3747 30.9509
NB4 GDSC1; CTRP2 1.4272 3.9235 1.3888 30.8887
Hs 611.T CTRP2 1.4567 3.1509 1.4526 30.5776
KMS-21-BM CTRP2 1.4659 4.1104 1.4134 30.6781
Namalwa GDSC1; CTRP2 1.4812 3.217 1.4763 30.417
BV-173 GDSC1; CTRP2 1.492 4.3455 1.4162 30.5821
SCC-3 GDSC1 1.5014 3.0156 1.3602 19.6596
KY821 GDSC1 1.518 4.2895 0.9113 22.6784
OPM-2 GDSC1; CTRP2 1.5191 2.7071 1.5188 30.1492
MOLP-8 GDSC1; CTRP2 1.533 2.8846 1.5322 30.0585
SU-DHL-6 GDSC1; CTRP2 1.5351 3.2247 1.5307 30.0562
Jurkat CTRP2 1.5433 3.5179 1.5314 30.0267
PF-382 GDSC1; CTRP2 1.5519 3.3596 1.545 29.9527
LAMA-84 GDSC1; CTRP2 1.5872 4.7515 1.4624 30.1128
PL21 CTRP2 1.5901 3.6211 1.5753 29.7244
SU-DHL-4 GDSC1; CTRP2 1.6039 2.8462 1.6035 29.5845
P31/FUJ GDSC1; CTRP2 1.6049 4.622 1.5007 29.9259
Ri-1 CTRP2 1.6083 4.8947 1.4616 30.0461
EB1 CTRP2 1.6144 3.3315 1.609 29.5314
Peer CTRP2 1.6788 3.2232 1.676 29.0934
ATN-1 GDSC1 1.6949 3.7584 1.3152 18.9154
SUP-M2 GDSC1; CTRP2 1.7027 2.3711 1.7027 28.9249
MM1.S CTRP2 1.7042 3.4283 1.698 28.9356
BE-13 GDSC1 1.7382 3.4377 1.4828 17.4986
DND-41 GDSC1 1.7434 3.6303 1.4167 17.9384
MOLT-4 GDSC1 1.8006 3.9387 1.3536 18.093
EM-2 GDSC1; CTRP2 1.8342 4.2856 1.7841 28.2175
KYO-1 CTRP2 1.8508 3.3566 1.8478 27.9486
KMS-12-BM GDSC1; CTRP2 1.8525 3.5979 1.8444 27.954
Farage GDSC1 1.8547 3.2337 1.6793 15.4883
MY-M12 GDSC1 1.8615 3.3045 1.6628 15.5666
TALL-1 [Human adult T-ALL] CTRP2 1.8745 4.1518 1.8381 27.9024
CMK CTRP2 1.8852 2.503 1.8852 27.7091
L-1236 GDSC1 1.8926 5.4875 0.7451 21.9461
KOPN-8 GDSC1 1.9087 4.3192 1.3013 17.9309
KO52 CTRP2 1.9209 3.5721 1.9147 27.4921
SU-DHL-10 CTRP2 1.9303 3.1586 1.9296 27.4113
Daudi GDSC1; CTRP2 1.9386 3.4778 1.9346 27.3666
KMS-26 CTRP2 1.9387 3.8106 1.925 27.3985
MOLT-3 CTRP2 1.946 2.7603 1.946 27.3039
SKM-1 GDSC1; CTRP2 1.9492 2.9891 1.949 27.2836
KMS-20 CTRP2 1.9633 3.5113 1.959 27.2033
QIMR-WIL GDSC1 1.9662 4.5858 1.239 18.1073
NOMO-1 GDSC1; CTRP2 1.9711 4.9159 1.8485 27.552
KMS-27 CTRP2 1.9883 3.6771 1.9805 27.0486
MOLM-6 CTRP2 1.9931 4.0736 1.9672 27.0772
SU-DHL-8 GDSC1; CTRP2 1.9959 3.0809 1.9956 26.9729
L-363 GDSC1; CTRP2 1.9975 4.1385 1.9674 27.0619
HAL-01 GDSC1 2.0009 5.883 0.6598 22.0081
KE-37 GDSC1; CTRP2 2.0041 4.1575 1.9729 27.0217
OCI-AML-3 GDSC1; CTRP2 2.0183 2.9597 2.0182 26.8229
HDLM-2 GDSC1; CTRP2 2.029 6.6091 1.4959 28.5692
SUP-T1 GDSC1; CTRP2 2.0375 3.3196 2.0363 26.6984
PL-21 GDSC1 2.0464 8.8456 -0.7511 29.4514
JSC-1 GDSC1 2.0585 3.3347 1.865 13.0783
SET-2 CTRP2 2.0724 2.771 2.0724 26.4622
HEL GDSC1; CTRP2 2.0859 4.9627 1.9644 26.7842
CA46 GDSC1; CTRP2 2.0874 4.1221 2.0619 26.4474
Mino CTRP2 2.1021 2.9326 2.1021 26.2643
BDCM CTRP2 2.1135 3.4031 2.1121 26.193
KMS-28BM CTRP2 2.1413 5.56 1.9066 26.806
HH [Human lymphoma] GDSC1 2.1548 4.2448 1.5839 14.6543
MOTN-1 CTRP2 2.1666 4.6957 2.09 26.0935
M-07e CTRP2 2.1673 3.7075 2.1618 25.8483
KMS-34 CTRP2 2.1696 3.2716 2.1691 25.8161
U266B1 GDSC1; CTRP2 2.1704 4.1341 2.1473 25.8866
Karpas-422 GDSC1; CTRP2 2.1794 2.8875 2.1794 25.7491
KMOE-2 GDSC1 2.1808 4.4295 1.5249 14.9739
RPMI-8226 GDSC1; CTRP2 2.1923 4.8106 2.1018 25.9695
JVM-3 GDSC1; CTRP2 2.1953 3.8961 2.1847 25.6788
OCI-M1 GDSC1; CTRP2 2.1976 2.8052 2.1976 25.6277
WSU-DLCL2 GDSC1; CTRP2 2.2026 3.6325 2.1991 25.6064
MOLT-13 CTRP2 2.221 3.8852 2.2113 25.5046
SUP-HD1 GDSC1; CTRP2 2.221 4.2698 2.1906 25.5741
L-540 GDSC1; CTRP2 2.2314 3.1511 2.2313 25.4028
NU-DHL-1 CTRP2 2.2393 3.0506 2.2392 25.3505
P12-Ichikawa CTRP2 2.2543 4.3305 2.2206 25.3633
LC4-1 GDSC1 2.2587 4.3658 1.6316 13.8092
MHH-CALL-3 CTRP2 2.2613 8.1759 1.1869 28.8625
MHH-CALL-4 CTRP2 2.2663 3.5175 2.2648 25.175
HuNS1 CTRP2 2.2934 4.4279 2.2533 25.1246
RCH-ACV CTRP2 2.3105 4.6017 2.254 25.0665
DB GDSC1; CTRP2 2.321 3.2581 2.3208 24.8064
Kasumi-2 CTRP2 2.3307 4.0259 2.3183 24.7828
GDM-1 GDSC1; CTRP2 2.3421 7.6134 1.4884 27.6175
MC116 GDSC1; CTRP2 2.3495 3.4886 2.3487 24.6187
Granta-519 GDSC1; CTRP2 2.3649 3.4898 2.3642 24.5156
HC-1 GDSC1 2.3713 6.2363 0.8321 19.1889
THP-1 GDSC1; CTRP2 2.3779 4.0813 2.3644 24.4719
MHH-PREB-1 GDSC1 2.3977 4.6028 1.6543 13.0081
TF-1 CTRP2 2.3991 3.5263 2.3983 24.2881
JJN-3 GDSC1; CTRP2 2.401 3.6683 2.3989 24.2799
HL-60 GDSC1; CTRP2 2.4092 4.3305 2.3823 24.3086
RPMI-6666 GDSC1; CTRP2 2.4192 5.1035 2.2996 24.5589
OCI-Ly3 CTRP2 2.445 3.3942 2.4448 23.9804
P32/ISH GDSC1 2.4486 3.1263 2.3596 7.4886
KM-H2 GDSC1; CTRP2 2.4834 5.4256 2.308 24.3254
K-562 GDSC1; CTRP2 2.506 3.4924 2.5057 23.5742
HPB-ALL CTRP2 2.547 3.4374 2.5468 23.3008
ST486 GDSC1; CTRP2 2.5631 3.8062 2.5607 23.2006
CCRF-CEM GDSC1 2.5641 4.7252 1.7518 11.5398
OCI-Ly10 CTRP2 2.5702 4.5647 2.5315 23.2761
JeKo-1 CTRP2 2.6313 4.3889 2.6092 22.8129
BALL-1 GDSC1 2.6444 6.9658 0.7135 18.8641
SUP-T11 CTRP2 2.6769 3.453 2.6768 22.435
MEG-01 GDSC1 2.693 6.3279 1.0738 16.1444
HEL 92.1.7 CTRP2 2.7107 5.0335 2.6241 22.504
KG-1 GDSC1 2.7456 6.8001 0.884 17.2886
DG-75 GDSC1 2.7456 5.6984 1.4333 13.2563
Ci-1 CTRP2 2.7524 3.2557 2.7524 21.9317
SUP-B15 GDSC1; CTRP2 2.7579 4.4874 2.734 21.9752
HD-MY-Z CTRP2 2.7746 4.2953 2.7624 21.8245
AMO1 GDSC1; CTRP2 2.7877 4.3848 2.7714 21.7512
U-937 CTRP2 2.8103 3.8954 2.8089 21.5507
ARH-77 GDSC1 2.8165 5.9423 1.3733 13.4368
BL-70 CTRP2 2.8634 4.3358 2.8519 21.2308
EJM GDSC1; CTRP2 2.8779 4.3443 2.8664 21.1342
L-428 GDSC1; CTRP2 2.8961 4.3959 2.8827 21.0194
LP-1 GDSC1; CTRP2 2.9066 4.4118 2.8927 20.9512
KMS-18 CTRP2 2.9095 5.5658 2.741 21.4656
EHEB GDSC1; CTRP2 2.9184 4.823 2.8725 20.9808
KCL-22 GDSC1; CTRP2 2.9257 5.1055 2.8437 21.0559
Hs 445 GDSC1 2.9286 7.622 0.6293 18.3127
MN-60 GDSC1 2.9344 4.7772 2.0562 7.6841
VL51 GDSC1 2.9393 5.1672 1.8654 9.1655
MJ CTRP2 2.9399 6.9303 2.3789 22.6781
Ramos.2G6.4C10 GDSC1 2.9609 5.7223 1.6061 11.1079
Jiyoye GDSC1 3.1357 4.515 2.3524 4.6372
CTB-1 GDSC1 3.1419 7.7782 0.7281 16.8598
MLMA GDSC1 3.1437 4.8725 2.1806 5.9597
GR-ST GDSC1 3.2099 6.2384 1.5523 10.6354
HT GDSC1; CTRP2 3.2436 3.957 3.2435 18.6598
SK-MM-2 GDSC1; CTRP2 3.2879 5.146 3.2253 18.5765
RPMI-8866 GDSC1 3.3342 5.029 2.2487 4.8189
ME1 CTRP2 3.3509 6.5616 2.949 19.3726
MOLP-2 CTRP2 3.3663 5.6131 3.2272 18.3209
BC-3 GDSC1 3.379 6.3232 1.6427 9.3756
RL GDSC1; CTRP2 3.5172 3.9401 3.5172 16.8366
Loucy GDSC1 3.519 7.6423 1.0959 12.9906
BC-1 GDSC1 3.7352 7.1146 1.5186 9.2097
CESS GDSC1 3.9334 7.4871 1.4787 8.9292
WSU-NHL GDSC1 4.362 7.3337 1.8356 5.2474
TUR GDSC1 4.6762 6.4791 2.3797 1.2504
JVM-2 GDSC1 4.7634 7.9338 1.8015 4.6366
U-698-M GDSC1 4.7807 8.1596 1.7097 5.2179
ROS-50 GDSC1 5.0758 10.8934 0.6203 11.719
IM-9 GDSC1 5.1113 6.3548 2.601 0.1676
EB2 GDSC1 5.2398 10.3185 0.9963 8.9522
P30/OHK GDSC1 5.2443 11.784 0.3082 13.173
Karpas-620 GDSC1; CTRP2 5.5921 9.2431 4.0541 9.2802
ME1 GDSC1 5.6058 17.1503 -2.0385 23.0441
YT GDSC1 5.6791 13.0832 -0.0217 13.9613
REC-1 CTRP2 6.2379 11.5206 3.4658 10.442
P3HR-1 CTRP2 6.6937 18.8297 0.1845 21.3071
Raji GDSC1; CTRP2 7.5048 9.1779 5.4626 0.6954
Reh GDSC1; CTRP2 7.787 9.3679 5.5144 0.4076
⏷ Show the Full List of 208 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 2.157 3.6279 2.153 25.9118
TE15 CTRP2 2.7439 6.2975 2.3703 23.2968
TE-15 GDSC1 -0.903 4.5203 -1.7535 49.188
TE-11 GDSC1; CTRP2 1.2547 4.1723 1.1846 32.1421
TE-8 GDSC1 1.3176 3.6744 0.944 23.5303
TE-10 GDSC1; CTRP2 1.8649 5.371 1.6479 28.5797
OE21 CTRP2 2.5456 3.477 2.5453 23.3104
KYSE-410 CTRP2 2.7097 5.9572 2.4286 23.1935
KYSE-70 CTRP2 2.7864 4.3297 2.7729 21.7503
TE-4 CTRP2 3.1519 4.7034 3.1288 19.3481
KYSE-140 CTRP2 3.2968 6.7829 2.816 20.0225
TE-9 GDSC1; CTRP2 3.321 4.2837 3.3193 18.1492
TE-5 GDSC1; CTRP2 3.362 4.1758 3.3615 17.872
TE-14 CTRP2 3.4329 5.1793 3.3756 17.5924
COLO 680N CTRP2 3.4823 6.198 3.2048 18.0448
TE-1 GDSC1; CTRP2 3.5343 6.0836 3.2943 17.5632
KYSE-30 CTRP2 3.5797 5.2963 3.5158 16.6375
KYSE-180 CTRP2 3.7143 5.676 3.5918 15.9456
TE-6 GDSC1 3.8133 6.276 1.9802 5.5255
OE19 CTRP2 4.4626 6.1246 4.2956 11.1252
KYSE-520 CTRP2 4.536 6.2708 4.3312 10.7754
EC-GI-10 GDSC1; CTRP2 4.7268 6.4794 4.4679 9.7099
KYSE-450 CTRP2 4.9561 7.284 4.384 9.4104
OE33 CTRP2 5.1501 6.2632 5.001 6.4909
KYSE-150 CTRP2 6.7287 15.1213 2.0628 15.0466
KYSE-510 CTRP2 7.8225 17.9294 1.5108 15.1008
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 4.0438 5.9454 3.8873 13.8733
MZ-PC-1 GDSC1 1.7112 3.5927 1.3966 18.2511
Hs 766T CTRP2 1.8425 4.8547 1.7202 28.407
PaTu 8988s CTRP2 2.133 4.9809 2.012 26.4691
MIA PaCa-2 CTRP2 2.2159 2.9097 2.2159 25.5063
KP-3 CTRP2 2.2355 6.9909 1.5955 27.5831
Panc 03.27 CTRP2 2.4815 3.4102 2.4813 23.7374
SNU-410 CTRP2 2.5434 10.1884 0.6339 29.7138
PSN1 GDSC1; CTRP2 2.6127 4.4765 2.5835 22.9606
SW1990 CTRP2 2.6146 4.3008 2.5973 22.9078
PK-59 CTRP2 2.6217 4.7297 2.5691 22.9801
HuP-T4 CTRP2 2.6338 4.526 2.6016 22.83
DAN-G CTRP2 2.6779 6.3623 2.279 23.825
BxPC-3 CTRP2 2.732 4.6855 2.6902 22.2086
HPAC CTRP2 2.8004 4.1344 2.7946 21.6315
TCC-Pan2 CTRP2 2.9983 6.4294 2.6075 21.6716
QGP-1 CTRP2 3.097 5.1582 3.0193 19.9002
Panc 08.13 CTRP2 3.1332 4.645 3.1134 19.4612
AsPC-1 CTRP2 3.3013 5.5234 3.1753 18.7077
Panc 05.04 CTRP2 3.302 5.2711 3.2217 18.5437
SUIT-2 CTRP2 3.359 5.2648 3.2839 18.1459
Panc 10.05 CTRP2 3.3938 4.8893 3.3667 17.7499
KP-2 CTRP2 3.4742 4.7813 3.4586 17.1754
PaTu 8902 CTRP2 3.4907 5.2106 3.4329 17.2092
SU.86.86 CTRP2 3.5042 4.3522 3.5031 16.9266
HuP-T3 CTRP2 3.6033 5.5682 3.4936 16.6396
Capan-1 CTRP2 3.642 5.6056 3.528 16.397
SNU-213 CTRP2 3.7842 5.3645 3.7246 15.2604
KP-4 CTRP2 3.9715 5.3179 3.9313 13.9459
PK-45H CTRP2 4.0078 6.4639 3.6946 14.684
HPAF-II CTRP2 4.0417 7.8169 3.2091 16.4426
CFPAC-1 CTRP2 4.0461 5.611 3.9647 13.5918
YAPC CTRP2 4.1181 5.3178 4.0869 12.9387
L3.3 CTRP2 4.3049 5.4328 4.2714 11.7022
Panc 04.03 CTRP2 4.3756 5.6221 4.3186 11.3123
Panc 02.03 CTRP2 4.5736 6.0246 4.4447 10.249
PaTu 8988t CTRP2 4.842 8.7482 3.5948 12.8743
Capan-2 CTRP2 4.862 7.416 4.2295 10.2673
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 62 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 2.1447 3.4012 2.1435 43.3944
Hs 940.T CTRP2 1.1862 3.0603 1.1804 32.3853
SH-4 GDSC1 1.8313 3.449 1.5788 16.3205
IST-MEL1 GDSC1 1.9052 5.6053 0.7014 22.1798
Malme-3M CTRP2 1.9588 5.9634 1.6075 28.4153
CP67-MEL GDSC1 1.9845 4.0348 1.5039 16.0734
COLO 792 CTRP2 2.0198 3.2924 2.0187 26.8161
RVH-421 CTRP2 2.0557 3.8173 2.0447 26.61
Mel Ho CTRP2 2.3261 3.8253 2.3203 24.7912
Hs 934.T CTRP2 2.3336 3.0218 2.3336 24.722
G-361 CTRP2 2.3374 3.3972 2.3369 24.6981
HT-144 GDSC1; CTRP2 2.3412 2.8924 2.3412 24.6711
RPMI-7951 CTRP2 2.3475 3.6899 2.3446 24.6388
Hs 294T CTRP2 2.3503 2.8125 2.3503 24.6107
WM88 CTRP2 2.3589 3.2196 2.3588 24.5538
MeWo CTRP2 2.3769 3.9871 2.3671 24.4663
UACC-257 GDSC1; CTRP2 2.4311 2.8305 2.4311 24.0721
IGR-1 CTRP2 2.4411 3.0917 2.4411 24.0056
SK-MEL-3 CTRP2 2.45 2.9396 2.45 23.9464
A2058 CTRP2 2.453 2.8358 2.453 23.9267
SK-MEL-24 CTRP2 2.4895 2.9809 2.4895 23.6832
MMAc-SF GDSC1 2.4924 4.7343 1.6804 12.3956
Hs 852.T CTRP2 2.5001 3.8636 2.496 23.626
SK-MEL-5 CTRP2 2.5051 2.9633 2.5051 23.5792
MZ-MEL-7 GDSC1 2.5386 3.6161 2.2556 7.7878
WM115 CTRP2 2.579 2.9015 2.579 23.0867
Hs 936.T CTRP2 2.5933 3.294 2.5933 22.992
GAK GDSC1 2.6254 3.6249 2.3388 6.7516
WT2-iPS CTRP2 2.6661 3.25 2.6661 22.5067
IPC-298 CTRP2 2.7043 3.7032 2.7037 22.2543
SK-MEL-30 CTRP2 2.7731 3.3761 2.7731 21.7938
Hs 895.T CTRP2 2.8141 5.8929 2.5593 22.4059
SK-MEL-1 GDSC1; CTRP2 2.8484 3.9067 2.8471 21.2966
IGR-37 CTRP2 2.8646 3.5811 2.8646 21.1841
LOX-IMVI GDSC1; CTRP2 2.8829 4.4849 2.8641 21.1252
MZ-MEL-2 GDSC1 2.9359 4.7092 2.0914 7.401
K029AX CTRP2 3.0342 4.3571 3.0261 20.0816
Mel JuSo CTRP2 3.0642 5.0727 2.9966 20.0835
COLO 829 GDSC1; CTRP2 3.0789 5.2479 2.9855 20.075
WM983B CTRP2 3.1036 5.0969 3.0353 19.8239
MDA-MB-435S CTRP2 3.1249 4.8746 3.0852 19.5842
A-375 CTRP2 3.1262 4.9373 3.0797 19.5985
Hs 944.T CTRP2 3.13 5.089 3.0646 19.6377
Hs 688(A).T CTRP2 3.1315 4.8321 3.0964 19.5246
A101D GDSC1; CTRP2 3.1393 4.91 3.0967 19.498
IGR-39 CTRP2 3.2755 4.9826 3.2327 18.5915
HMCB CTRP2 3.3971 5.1537 3.3409 17.8272
WM266-4 CTRP2 3.4696 5.4903 3.364 17.5155
UACC-62 CTRP2 3.4803 5.0418 3.4427 17.2093
WM1799 CTRP2 3.5201 5.4881 3.419 17.1634
WM793 CTRP2 3.6501 5.1932 3.6051 16.1032
A-388 GDSC1 3.7756 8.7995 0.7185 14.7636
DJM-1 GDSC1 3.7814 5.6198 2.27 3.4662
SK-MEL-31 CTRP2 4.0041 5.9242 3.8494 14.1306
SK-MEL-28 CTRP2 4.112 5.5541 4.0464 13.0979
COLO 800 GDSC1; CTRP2 4.3067 5.814 4.2055 11.9262
CJM [Human melanoma] CTRP2 4.3513 5.5384 4.3062 11.433
LB373-MEL-D GDSC1 4.3812 6.2181 2.344 1.832
SK-MEL-2 GDSC1; CTRP2 4.5982 4.9778 4.5981 9.635
LB2518-MEL GDSC1 4.6161 6.089 2.5059 0.7201
CP66-MEL GDSC1 4.892 6.2125 2.5706 0.3159
Hs 839.T CTRP2 5.1555 10.1514 3.21 13.718
⏷ Show the Full List of 62 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-12 GDSC1 -0.2292 4.8301 -1.1506 43.2816
HCE-4 GDSC1 1.9398 3.3308 1.7383 14.6116
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; CTRP2 3.72 5.4616 3.6397 15.7596
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB1 GDSC1; CTRP2 1.2698 3.3851 1.2564 31.8536
SK-N-AS CTRP2 2.1988 3.2122 2.1986 25.6206
MHH-NB-11 GDSC1; CTRP2 2.2202 4.4936 2.17 25.6465
SK-N-DZ GDSC1; CTRP2 2.246 3.3666 2.2454 25.3077
KP-N-SI9s CTRP2 2.2496 3.2484 2.2494 25.282
SK-N-BE(2) CTRP2 2.291 4.8068 2.2077 25.2879
NB(TU)1 GDSC1 2.3101 5.0115 1.3741 15.5213
SK-N-SH CTRP2 2.3523 3.0465 2.3523 24.5973
Kelly GDSC1; CTRP2 2.3587 3.3417 2.3585 24.5553
NH-6 CTRP2 2.4137 3.1555 2.4136 24.1885
CHP-212 CTRP2 2.4257 3.1713 2.4257 24.1082
TGW GDSC1 2.4801 4.4086 1.8264 11.3258
KP-N-RT-BM-1 GDSC1 2.8592 4.942 1.9093 9.1226
IMR-5 GDSC1 2.9344 4.7555 2.067 7.5983
GOTO GDSC1 3.0109 5.0737 1.9722 8.0638
CHP-126 GDSC1; CTRP2 3.176 3.9246 3.1759 19.1099
SJNB-14 GDSC1 3.2137 5.3638 1.9911 7.213
LA-N-6 GDSC1 3.2149 6.5986 1.3765 11.9536
SJNB-13 GDSC1 3.3375 6.0302 1.7561 8.6371
KP-N-YN GDSC1; CTRP2 3.3642 5.9092 3.1552 18.5834
KP-N-YS GDSC1 3.432 5.5715 2.0541 6.0313
SK-N-BE(2)-M17 GDSC1 3.4518 5.0633 2.3163 3.9593
SK-N-FI GDSC1 3.5079 6.5997 1.6039 9.2611
NH-12 GDSC1 3.7249 5.787 2.1545 4.4537
SJNB-7 GDSC1 4.0179 7.2895 1.6329 7.562
SJNB-6 GDSC1 4.2044 6.4273 2.1556 3.3557
SJNB-17 GDSC1 4.2136 6.141 2.2884 2.4526
SiMa GDSC1 4.6541 6.8434 2.2189 2.1672
SJNB-5 GDSC1 4.6878 9.2232 1.1576 9.1994
NB69 GDSC1 5.3836 12.7009 -0.0365 14.765
SJNB-10 GDSC1 5.4199 7.4454 2.3282 0.8057
GI-ME-N GDSC1 6.6653 8.9893 2.2504 0.4068
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 2.6195 3.3738 2.6194 22.8174
SNU-478 CTRP2 2.7521 4.5165 2.726 22.0214
HuCC-T1 CTRP2 2.8427 4.7824 2.7969 21.4848
HuH-28 CTRP2 2.9508 4.3218 2.9421 20.6389
SNU-308 CTRP2 3.4362 5.7937 3.2623 17.9787
SNU-1196 CTRP2 3.5586 5.7056 3.416 17.0528
SNU-869 CTRP2 4.3795 5.4742 4.3454 11.2073
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NOS-1 [Human HNSCC] GDSC1 -5.4708 2.4061 -6.0893 75.817
ES6 GDSC1 -0.3643 4.7875 -1.2776 44.5132
EW-16 GDSC1 0.8344 4.164 0.2413 30.7381
SK-ES-1 GDSC1; CTRP2 1.1019 3.6774 1.0678 33.0408
A-673 CTRP2 1.3845 3.2795 1.3768 31.0707
Hs 888.T CTRP2 1.4298 3.2616 1.4233 30.7648
ES4 GDSC1 1.5698 3.5708 1.2531 20.0198
H-EMC-SS GDSC1 1.5788 3.8926 1.1388 20.7745
MHH-ES-1 CTRP2 1.6946 4.3353 1.6318 29.1899
EW-1 GDSC1 1.705 3.804 1.3078 18.9153
U2OS CTRP2 1.8292 4.6953 1.7301 28.4165
SK-N-MC CTRP2 1.841 2.7492 1.841 28.0037
TC71 CTRP2 2.2499 3.7787 2.244 25.2992
CAL-78 CTRP2 2.3642 4.7665 2.2911 24.7653
ES8 GDSC1 2.4319 3.1178 2.3443 7.6871
MG-63 CTRP2 2.4512 2.9435 2.4512 23.9387
EW-3 GDSC1 2.6694 5.032 1.6969 11.5301
SaOS-2 CTRP2 2.7603 3.5915 2.7602 21.8794
SK-PN-DW GDSC1 2.8088 5.1722 1.7507 10.5578
G-292 clone A141B1 CTRP2 2.9523 5.4066 2.8202 21.0529
SJSA-1 GDSC1; CTRP2 3.0147 5.3874 2.8915 20.6063
ES1 GDSC1 3.123 5.7594 1.7214 9.6303
Hs 822.T CTRP2 3.2264 4.7616 3.202 18.8558
SW1353 CTRP2 3.2459 4.3453 3.2422 18.6566
EW-11 GDSC1 3.5542 6.0399 1.9135 6.7511
ES5 GDSC1 4.0842 6.9019 1.8617 5.713
EW-24 GDSC1 4.3861 5.7802 2.5255 0.8456
EW-18 GDSC1 4.3992 8.1612 1.4716 7.741
HOS CTRP2 4.4084 9.3826 2.8724 16.8268
EW-12 GDSC1 4.426 6.7368 2.1435 3.0128
EW-13 GDSC1 4.6391 7.7598 1.8076 4.8465
TC-71 GDSC1 4.8002 6.2988 2.5033 0.5879
ES7 GDSC1 4.946 11.5781 0.2044 14.5444
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 75 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC1; CTRP2 1.9563 3.459 1.9529 27.2467
HCC1500 CTRP2 2.325 3.7546 2.3207 24.7935
Hs 578T CTRP2 2.3719 3.2949 2.3718 24.467
MDA-MB-468 CTRP2 2.3744 3.0961 2.3744 24.4501
Evsa-T GDSC1 2.4433 3.7479 2.0999 9.4111
CAL-85-1 CTRP2 2.46 3.5534 2.4592 23.8825
CAL-51 CTRP2 2.7716 4.639 2.7362 21.9232
HMC-1-8 CTRP2 2.7895 4.0248 2.7861 21.6961
OCUB-M GDSC1 2.791 5.0054 1.8182 10.1001
MCF-7 CTRP2 2.7992 5.2958 2.6755 22.0431
HCC1599 GDSC1 2.8312 5.4408 1.6362 11.3627
HCC1395 CTRP2 2.8943 3.978 2.8926 20.9921
BT-474 GDSC1; CTRP2 2.9476 3.7382 2.9474 20.632
HDQ-P1 CTRP2 2.9503 5.2718 2.8429 20.98
AU565 CTRP2 3.0522 4.4539 3.0406 19.9732
CAL-148 GDSC1; CTRP2 3.0749 4.0621 3.0737 19.7873
MDA-MB-453 CTRP2 3.0781 4.5291 3.0635 19.8108
KPL-1 CTRP2 3.0832 4.1446 3.0811 19.7347
HCC1954 CTRP2 3.2327 4.2276 3.2309 18.7381
MRK-nu-1 GDSC1 3.2769 4.7095 2.3636 4.1013
HCC2218 GDSC1; CTRP2 3.3971 4.8231 3.3755 17.7092
HCC1143 CTRP2 3.4904 5.659 3.3521 17.4917
MDA-MB-231 CTRP2 3.5821 5.7265 3.4369 16.9059
HCC1806 CTRP2 3.6127 5.4265 3.5302 16.4818
HCC1187 GDSC1 3.6318 6.6656 1.6633 8.4295
HCC202 CTRP2 3.7168 5.6584 3.5983 15.9147
CAL-120 CTRP2 3.7338 5.4702 3.6531 15.6694
HCC38 CTRP2 3.9235 5.6451 3.8253 14.467
MDA-MB-361 CTRP2 4.0171 5.0332 4.0057 13.5441
ZR-75-1 CTRP2 4.2879 5.6403 4.2208 11.9314
HCC1428 CTRP2 4.3218 5.0268 4.3189 11.4858
HCC1937 CTRP2 4.3946 5.7313 4.3187 11.252
BT-549 CTRP2 4.4884 5.9482 4.3715 10.7728
HCC2157 GDSC1 4.4962 7.5759 1.8061 5.1585
COLO 824 GDSC1 4.5369 7.8858 1.6882 5.8889
CAMA-1 CTRP2 4.5408 5.7605 4.4714 10.2554
MDA-MB-157 CTRP2 4.5745 7.2455 4.0055 11.9075
JIMT-1 CTRP2 4.8202 5.7692 4.7722 8.3201
BT-20 CTRP2 5.3278 6.2585 5.195 5.2511
MFM-223 GDSC1 5.3438 6.668 2.5761 0.1526
ZR-75-30 CTRP2 5.4751 6.1336 5.3967 4.0709
HCC1419 CTRP2 5.6327 6.7176 5.324 3.9291
T-47D CTRP2 7.9598 18.1294 1.5144 14.8624
BT 330 CTRP2 2.5082 2.9986 2.5082 23.5585
BT164 CTRP2 2.5631 2.9385 2.5631 23.193
BT 228 CTRP2 2.5725 2.9924 2.5725 23.1301
BT 286 CTRP2 2.6136 3.0901 2.6136 22.8566
BT 131 CTRP2 2.6239 3.1555 2.6239 22.7877
BT 440 CTRP2 2.6337 3.8981 2.6307 22.7324
BT 416 CTRP2 2.6979 3.6103 2.6976 22.2957
BT 231 CTRP2 2.7032 3.583 2.7031 22.2599
BT 112 CTRP2 2.7172 3.3771 2.7172 22.1665
BT147 CTRP2 2.769 3.3739 2.769 21.8212
BT 239 CTRP2 2.8335 3.3973 2.8334 21.3918
BT 504 CTRP2 2.9154 3.497 2.9154 20.8457
BT 340 CTRP2 3.0421 3.8097 3.042 20.0021
BT 245 CTRP2 3.0446 4.3517 3.037 20.0106
BT 248 CTRP2 3.0753 4.0738 3.074 19.7848
BT 444 CTRP2 3.1664 4.0682 3.1657 19.176
BT 359 CTRP2 3.2355 4.1984 3.2341 18.7181
BT 187 CTRP2 3.2445 5.404 3.1368 19.0216
BT 232 CTRP2 3.2888 3.958 3.2887 18.3585
BT 139 CTRP2 3.2921 3.9383 3.2921 18.3361
BT 498 CTRP2 3.392 4.4318 3.3885 17.6821
BT 482 CTRP2 3.453 4.0055 3.453 17.2642
BT 333 CTRP2 3.4613 4.1082 3.4612 17.2094
BT 172 CTRP2 3.4626 4.0401 3.4626 17.2003
BT 159 CTRP2 3.5192 4.0601 3.5192 16.823
BT 422 CTRP2 3.7007 4.1828 3.7007 15.6138
BT 216 CTRP2 3.7172 4.3334 3.717 15.5046
BT 328 CTRP2 4.245 5.6129 4.1794 12.2119
BT 145 CTRP2 4.2814 5.6374 4.2142 11.9751
BT 320 CTRP2 4.3324 5.2678 4.3174 11.4559
BT 224 CTRP2 4.4523 5.7075 4.386 10.8341
BT 179 CTRP2 4.6239 5.7015 4.5725 9.6393
⏷ Show the Full List of 75 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 2.9267 4.612 2.9008 20.8577
Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KS-1 [Human Krukenberg tumour] GDSC1 0.763 3.098 0.5312 29.4317
CCF-STTG1 CTRP2 1.2075 5.0994 0.9905 32.9315
SF126 GDSC1; CTRP2 1.9162 6.0647 1.5336 28.802
SF268 GDSC1; CTRP2 2.0418 4.7056 1.9556 26.9573
GB-1 GDSC1; CTRP2 2.0646 4.9075 1.9504 26.9011
42-MG-BA CTRP2 2.1576 6.3139 1.7261 27.3783
U-118MG CTRP2 2.1857 5.0746 2.0529 26.1587
SF539 GDSC1; CTRP2 2.2906 6.445 1.8318 26.5963
GOS-3 CTRP2 2.3565 2.8985 2.3565 24.5695
KNS-60 CTRP2 2.3629 3.0114 2.3629 24.5269
GaMG CTRP2 2.4144 3.7456 2.4114 24.1935
SW1088 CTRP2 2.4163 3.2715 2.4163 24.1709
YH-13 CTRP2 2.4474 2.9427 2.4474 23.9639
Hs 683 CTRP2 2.4715 2.9681 2.4715 23.8028
M059K CTRP2 2.5461 2.8961 2.5461 23.306
TM-31 CTRP2 2.5533 4.2335 2.5375 23.3112
DK-MG CTRP2 2.5967 2.9567 2.5967 22.9691
GI-1 GDSC1 2.6062 10.1199 -0.8932 27.7714
LN-229 CTRP2 2.6257 4.3044 2.6085 22.8334
SNU-466 CTRP2 2.6824 3.0961 2.6824 22.3981
GMS-10 CTRP2 2.704 3.1289 2.704 22.2542
Onda 11 GDSC1 2.708 4.8575 1.8179 10.4323
LN-18 CTRP2 2.776 3.8102 2.7751 21.7777
KNS-81 CTRP2 2.7815 3.2912 2.7815 21.7376
D283 Med GDSC1; CTRP2 2.8111 4.3777 2.7959 21.5915
Onda 10 GDSC1 2.8585 4.2779 2.2396 6.5303
KG-1-C CTRP2 2.9741 5.3656 2.8516 20.8742
YKG-1 CTRP2 3.0184 4.6467 2.9938 20.2422
NMC-G1 GDSC1; CTRP2 3.0519 4.4364 3.0411 19.9724
SNU-626 CTRP2 3.0965 4.0094 3.0958 19.6419
ONS-76 GDSC1; CTRP2 3.1085 5.5141 2.968 20.042
KINGS-1 GDSC1 3.1773 4.533 2.3758 4.3174
T98G CTRP2 3.2024 5.8275 2.9993 19.6388
CAS-1 GDSC1; CTRP2 3.3147 3.9241 3.3147 18.1857
SNU-1105 CTRP2 3.3157 4.0397 3.3155 18.1795
A-172 CTRP2 3.3703 5.3825 3.2765 18.1357
SNU-201 CTRP2 3.4461 3.9581 3.4461 17.3103
U-251MG CTRP2 3.4667 4.7435 3.4531 17.2184
SNB-75 GDSC1; CTRP2 3.4728 5.2402 3.4096 17.3467
D-263MG GDSC1 3.6327 5.3679 2.2927 3.6598
SNU-489 CTRP2 3.6398 4.3431 3.6394 16.0211
KALS-1 GDSC1; CTRP2 3.8761 5.9152 3.7121 15.016
Daoy CTRP2 4.0426 6.2425 3.8027 14.1832
DBTRG-05MG CTRP2 4.2102 5.2967 4.1865 12.2996
KNS-42 GDSC1; CTRP2 4.343 5.4213 4.3133 11.4352
Becker GDSC1; CTRP2 4.4688 6.8381 4.0578 11.9956
AM-38 GDSC1 4.4855 6.3503 2.341 1.6991
D-336MG GDSC1 4.5723 7.1524 2.0415 3.4127
U-87MG ATCC GDSC1; CTRP2 4.5762 5.0179 4.5759 9.7825
SF295 CTRP2 4.6568 5.5506 4.6308 9.3325
D-247MG GDSC1 4.9822 12.7485 -0.3374 17.4032
SW1783 CTRP2 5.3186 9.2079 3.8234 10.834
8-MG-BA GDSC1; CTRP2 5.554 9.4703 3.9074 9.9727
D-502MG GDSC1 5.6095 7.7856 2.2786 0.8574
KNS-81-FD GDSC1 5.7594 7.3994 2.4734 0.2286
⏷ Show the Full List of 55 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 0.2334 4.1281 -0.3881 37.678
TGBC1TKB GDSC1 2.4942 4.6283 1.7336 11.979
TGBC24TKB GDSC1 4.4187 6.7365 2.1397 3.0514
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AN3-CA CTRP2 2.2338 5.2472 2.0731 25.9351
JHUEM-7 CTRP2 2.2833 3.8497 2.276 25.0814
JHUEM-2 CTRP2 2.5835 4.0424 2.5763 23.0807
ESS-1 CTRP2 2.6027 3.7814 2.6009 22.9352
RL95-2 GDSC1; CTRP2 2.791 5.3466 2.6572 22.1329
JHUEM-1 CTRP2 2.9581 4.225 2.9527 20.5795
HEC-1-A CTRP2 3.0589 4.8953 3.0132 20.0443
HEC-59 CTRP2 3.4227 5.4864 3.314 17.8384
HEC-151 CTRP2 3.5224 5.1901 3.4695 16.9812
EN CTRP2 3.5467 5.0826 3.5086 16.7687
MFE-296 CTRP2 3.6174 5.9488 3.4212 16.8529
HEC-6 CTRP2 3.6368 4.2927 3.6367 16.0401
HEC-1-B CTRP2 3.7451 5.8996 3.5731 15.9162
HEC-50B CTRP2 4.0791 6.3237 3.8173 14.021
KLE GDSC1; CTRP2 4.0841 5.9608 3.9273 13.6058
JHUEM-3 CTRP2 4.0988 5.9341 3.9502 13.4789
HEC-251 CTRP2 4.2053 5.753 4.1088 12.5848
EFE-184 CTRP2 4.3916 5.7531 4.311 11.2886
MFE-319 CTRP2 4.4859 5.0222 4.4851 10.3858
HEC-265 CTRP2 4.5294 5.2844 4.5212 10.1207
HEC-108 CTRP2 4.7152 5.2716 4.7126 8.8639
Ishikawa (Heraklio) 02 ER- CTRP2 4.6606 5.631 4.6236 9.3448
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB1047-RCC GDSC1 0.3119 6.3895 -1.2467 39.9687
LB996-RCC GDSC1 1.9109 7.5122 -0.2176 27.5656
TUHR14TKB CTRP2 2.0457 5.4827 1.8201 27.4092
HA7-RCC GDSC1 2.0901 4.0269 1.616 14.7269
RXF 393L GDSC1 2.1035 4.8588 1.2479 17.3943
KMRC-3 CTRP2 2.1091 3.7165 2.1024 26.24
CAL-54 CTRP2 2.1401 3.4309 2.1385 26.0163
UO-31 CTRP2 2.1633 5.0483 2.0333 26.2985
BB65-RCC GDSC1 2.3181 3.9227 1.8944 11.5502
KMRC-1 CTRP2 2.3503 3.1069 2.3502 24.611
KMRC-2 CTRP2 2.364 2.8807 2.364 24.5195
TK-10 GDSC1 2.4218 4.0138 1.9565 10.5942
786-O CTRP2 2.6097 4.4014 2.5859 22.9624
VMRC-RCZ CTRP2 2.6539 3.7654 2.6526 22.5924
VMRC-RCW CTRP2 2.7392 4.6621 2.7 22.1519
BFTC-909 CTRP2 2.9702 4.188 2.9659 20.4948
TUHR4TKB CTRP2 3.1091 4.8243 3.0736 19.675
A-704 GDSC1 3.324 6.4765 1.5238 10.4664
KMRC-20 CTRP2 3.3641 5.0327 3.3208 18.0029
Caki-2 CTRP2 3.4399 5.027 3.4017 17.4807
RCC10RGB GDSC1; CTRP2 3.5417 4.0122 3.5416 16.6736
769-P CTRP2 3.6783 5.5487 3.5787 16.1045
OS-RC-2 GDSC1; CTRP2 3.7263 7.4483 3.0293 17.9962
A-498 GDSC1; CTRP2 4.0938 5.44 4.045 13.1607
ACHN CTRP2 4.1798 7.5208 3.4778 15.0262
SNU-1272 CTRP2 4.2481 5.6097 4.1833 12.1889
TUHR10TKB CTRP2 4.4281 5.2425 4.4188 10.7991
Caki-1 CTRP2 6.3389 11.5157 3.5502 9.9057
LB2241-RCC GDSC1 6.8109 19.4078 -2.2862 21.1468
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KM12 GDSC1; CTRP2 -1.1059 4.407 -1.3806 47.863
SW48 CTRP2 0.6103 3.3778 0.577 36.3101
NCI-H716 GDSC1; CTRP2 1.5436 3.3061 1.5377 30.0046
LoVo CTRP2 1.8344 4.9742 1.6916 28.5301
HCT 15 CTRP2 1.9983 3.9507 1.9798 27.0174
SW948 CTRP2 2.1288 3.4891 2.1266 55.989
COLO 320HSR GDSC1 2.3268 3.5072 2.0841 10.1019
SNU-C1 GDSC1; CTRP2 2.4892 4.1431 2.4759 23.7296
C2BBe1 GDSC1; CTRP2 2.4917 3.8789 2.4872 23.6835
CL-11 GDSC1; CTRP2 2.5179 4.2822 2.4982 23.5599
HCC-56 CTRP2 2.5592 3.8515 2.5561 23.2291
COLO 320 CTRP2 2.5651 5.3434 2.4132 23.6998
T84 CTRP2 2.5935 3.6933 2.5924 22.994
SNU-C2A CTRP2 2.6557 5.7763 2.4158 23.4064
NCI-H508 CTRP2 2.6959 3.747 2.6951 22.3108
HT-55 CTRP2 2.7849 4.9328 2.7176 21.9435
SNU-1033 CTRP2 2.7916 4.0629 2.7875 21.6843
NCI-H747 GDSC1; CTRP2 2.833 4.148 2.8274 21.4133
SNU-C5 CTRP2 2.8532 5.6379 2.6638 21.9138
SNU-407 CTRP2 2.8679 4.8283 2.8185 21.329
CCK-81 CTRP2 2.8872 5.1949 2.7881 21.3716
LS513 GDSC1; CTRP2 2.9062 4.1178 2.9025 20.9196
SK-CO-1 CTRP2 2.9112 3.9968 2.9095 20.8795
SNU-175 CTRP2 2.934 6.631 2.4733 22.3516
SW1417 CTRP2 2.9629 4.658 2.9349 20.6235
COLO201 CTRP2 3.0622 5.7026 2.8764 20.5103
COLO 678 CTRP2 3.0893 5.7595 2.8925 20.369
RKO GDSC1; CTRP2 3.1004 5.056 3.0376 19.8262
OUMS-23 CTRP2 3.2062 4.0178 3.2058 18.9098
SW620 CTRP2 3.2977 6.1865 3.0069 19.3202
LS1034 GDSC1; CTRP2 3.3838 4.1968 3.3833 17.7269
SNU-61 CTRP2 3.4357 5.4569 3.3337 17.7287
SNU-503 CTRP2 3.4443 6.0347 3.2095 18.1429
SNU-C2B GDSC1 3.6801 5.8397 2.0991 4.9848
LS180 CTRP2 3.7065 5.2763 3.6543 15.7526
CW-2 GDSC1; CTRP2 3.714 5.2155 3.6703 15.6733
GP2d CTRP2 3.753 6.6566 3.3533 16.6966
COLO205 CTRP2 3.8823 5.9001 3.7226 14.9592
RCM-1 [Human ESC] CTRP2 4.0031 5.7335 3.8932 13.9781
LS411N GDSC1; CTRP2 4.0985 5.2692 4.0716 13.0545
LS123 GDSC1; CTRP2 4.1001 6.3175 3.8421 13.8671
MDST8 GDSC1; CTRP2 4.1333 5.209 4.1139 12.7974
DLD-1 CTRP2 4.2925 5.4659 4.2538 11.8025
HCT 116 CTRP2 4.4101 5.4108 4.3856 10.9709
HT-29 CTRP2 4.4157 5.3934 4.3934 10.9259
HCT 8 CTRP2 4.556 6.1777 4.3818 10.5301
SNU-C4 CTRP2 5.2532 5.9826 5.197 5.466
⏷ Show the Full List of 47 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 5.7044 7.231 2.5114 0.1753
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2 1.7485 3.7292 1.7333 28.6705
HuH-1 CTRP2 1.8349 3.8883 1.8145 28.1127
HuH-6 CTRP2 1.8846 3.8837 1.866 27.7755
Hep-G2 CTRP2 1.9016 3.19 1.9006 27.6031
SNU-886 CTRP2 2.2683 7.5832 1.4204 28.0731
JHH-1 CTRP2 2.3913 2.8318 2.3913 24.3375
HLF CTRP2 2.4373 3.0072 2.4373 24.0312
JHH-5 CTRP2 2.5753 4.5936 2.5342 23.2502
SNU-387 CTRP2 2.6094 3.811 2.6073 22.8914
SNU-423 CTRP2 2.6397 3.332 2.6397 22.6825
SNU-449 CTRP2 2.728 4.7358 2.6807 22.2537
JHH-4 CTRP2 2.9239 5.4623 2.7784 21.2889
Li-7 CTRP2 2.9914 4.5664 2.9714 20.4064
Hep 3B2.1-7 CTRP2 3.004 4.5927 2.9828 20.3266
SK-HEP-1 CTRP2 3.1681 4.9828 3.1189 19.3285
SNU-475 CTRP2 3.5809 5.0475 3.5484 16.5215
SNU-398 CTRP2 3.9063 6.4944 3.5743 15.4274
PLC/PRF/5 CTRP2 4.1574 5.4768 4.1077 12.7402
JHH-6 CTRP2 4.5976 4.9096 4.5975 9.6391
JHH-2 CTRP2 4.7266 7.1407 4.2083 10.7073
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 171 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1703 CTRP2 -4.3884 11.8285 -7.3145 59.0496
LC-2/ad GDSC1 0.0756 3.7635 -0.4284 38.9448
NCI-H2405 CTRP2 1.1605 5.9376 0.7432 33.8572
NCI-H2087 CTRP2 1.2183 5.7783 0.8477 33.3398
CAL-12T CTRP2 1.5233 3.9678 1.4857 30.246
DMS 454 CTRP2 1.5593 4.5217 1.4658 30.1936
LXF 289 GDSC1; CTRP2 1.6105 3.1875 1.6075 29.5494
COR-L51 CTRP2 1.743 3.8806 1.7198 28.7342
Ms-1 GDSC1 1.7685 3.2914 1.5665 16.7475
SK-MES-1 CTRP2 1.942 2.8427 1.942 27.3308
NCI-H847 GDSC1 1.9705 3.355 1.7628 14.2734
HCC44 CTRP2 2.0113 3.9723 1.992 26.9338
NCI-H1734 CTRP2 2.0615 4.099 2.0365 26.6186
NCI-H2228 CTRP2 2.1254 4.0672 2.1047 26.1785
NCI-H1341 CTRP2 2.1277 2.8906 2.1277 26.0937
NCI-H1755 CTRP2 2.1391 4.1124 2.1162 26.0945
HCC1833 CTRP2 2.1553 6.1735 1.7642 27.2541
NCI-H1435 CTRP2 2.1806 3.2271 2.1803 25.742
NCI-H1975 GDSC1; CTRP2 2.1887 4.9853 2.0713 26.086
NCI-H1563 CTRP2 2.193 3.975 2.1791 25.7051
NCI-H1568 CTRP2 2.2419 4.5715 2.1847 25.5255
HOP-62 GDSC1; CTRP2 2.2995 5.6307 2.0625 25.7634
LCLC-97TM1 CTRP2 2.3002 3.9562 2.2898 24.9794
NCI-H1184 CTRP2 2.3236 3.3041 2.3234 24.7892
EPLC-272H CTRP2 2.3301 4.8945 2.2371 25.0609
NCI-H1693 CTRP2 2.3491 3.8339 2.3434 24.6374
NCI-H1915 CTRP2 2.3939 3.0213 2.3939 24.3203
NCI-H810 CTRP2 2.4062 3.0619 2.4062 24.238
COLO 668 GDSC1; CTRP2 2.469 3.9828 2.4614 23.845
DV-90 CTRP2 2.4697 3.9769 2.4623 23.84
LUDLU-1 CTRP2 2.4699 3.1802 2.4699 23.814
NCI-H520 CTRP2 2.471 3.6291 2.4698 23.8104
NCI-H1694 GDSC1; CTRP2 2.4779 3.588 2.4771 23.7632
LK2 CTRP2 2.4998 2.8729 2.4998 23.6149
IST-SL1 GDSC1 2.5 4.723 1.6931 12.2656
SW1271 CTRP2 2.5229 4.2466 2.5055 23.519
NCI-H211 GDSC1; CTRP2 2.5378 3.199 2.5378 23.3616
LOU-NH91 CTRP2 2.5418 4.9037 2.4622 23.6047
NCI-H2196 GDSC1; CTRP2 2.5595 4.0707 2.5509 23.2456
NCI-H1105 CTRP2 2.5888 3.2125 2.5888 23.0218
COR-L95 GDSC1; CTRP2 2.6032 3.6067 2.6027 22.9274
NCI-H292 CTRP2 2.6181 4.4045 2.5944 22.9058
NCI-H647 CTRP2 2.6205 4.2679 2.605 22.8623
NCI-H1666 GDSC1; CTRP2 2.673 4.9321 2.5984 22.7136
NCI-H82 GDSC1 2.7253 5.2834 1.622 11.8858
HOP-92 CTRP2 2.7286 5.4104 2.5771 22.6101
NCI-H727 CTRP2 2.7316 4.5347 2.7032 22.1657
NCI-H2029 CTRP2 2.7357 4.1775 2.7273 22.0711
NCI-H1581 GDSC1; CTRP2 2.7371 5.1615 2.6321 22.3914
NCI-H522 CTRP2 2.7372 4.0735 2.732 22.0504
NCI-H2106 CTRP2 2.7558 4.8135 2.7015 22.0925
EBC-1 CTRP2 2.7759 3.8399 2.7748 21.779
HCC15 CTRP2 2.7982 5.868 2.5483 22.494
NCI-H1944 CTRP2 2.8034 4.4316 2.785 21.6536
NCI-H1355 GDSC1; CTRP2 2.813 6.5723 2.3607 23.1222
NCI-H1623 CTRP2 2.827 4.9766 2.7567 21.6731
NCI-H2110 CTRP2 2.8282 5.4901 2.6688 21.9745
NCI-H1648 GDSC1 2.8594 4.8226 1.969 8.6535
HCC1588 CTRP2 2.8623 4.2623 2.8537 21.2284
HCC2108 CTRP2 2.8647 5.2824 2.7487 21.5798
NCI-H2291 CTRP2 2.8731 5.2093 2.7705 21.4775
NCI-H1373 CTRP2 2.8817 4.9031 2.8243 21.2645
NCI-H209 GDSC1 2.9008 6.0283 1.4024 12.8947
NCI-H841 CTRP2 2.9066 5.6546 2.7181 21.5555
SK-LU-1 CTRP2 2.9302 5.2042 2.8328 21.0792
Lu-99 CTRP2 2.932 5.6842 2.7389 21.4024
NCI-H1385 CTRP2 2.9334 3.8736 2.9328 20.7277
NCI-H838 CTRP2 2.9336 4.6969 2.901 20.8343
DMS 273 CTRP2 2.9617 4.2639 2.9552 20.5594
COLO 699 CTRP2 2.9824 4.726 2.9497 20.5095
NCI-H2085 CTRP2 2.9876 5.8107 2.7692 21.1225
DMS 114 GDSC1; CTRP2 2.9935 4.099 2.9912 20.3332
NCI-H1573 CTRP2 2.9966 4.2586 2.991 20.3236
NCI-H1792 CTRP2 2.9973 5.5507 2.8396 20.843
NCI-H1304 GDSC1 3.0042 4.6886 2.1592 6.6159
NCI-H23 GDSC1; CTRP2 3.0092 5.0639 2.9391 20.4589
HCC95 CTRP2 3.0146 5.2316 2.9191 20.5106
NCI-H650 CTRP2 3.016 6.2901 2.6692 21.3947
LB647-SCLC GDSC1 3.0564 4.3622 2.3653 4.8047
NCI-H2009 CTRP2 3.0574 4.2378 3.0533 19.9136
DMS 79 GDSC1; CTRP2 3.0705 4.641 3.0485 19.8862
CPC-N GDSC1 3.1003 6.9148 1.1256 14.2205
A-549 CTRP2 3.1235 4.6277 3.1046 19.5228
PC-14 CTRP2 3.1498 5.2455 3.0622 19.5826
NCI-H358 CTRP2 3.2042 6.7908 2.7131 20.6738
NCI-H446 GDSC1; CTRP2 3.228 4.2124 3.2263 18.7689
NCI-H526 GDSC1; CTRP2 3.2443 4.7013 3.2251 18.7192
RERF-LC-A1 CTRP2 3.2611 6.1691 2.9719 19.5576
NCI-H69 GDSC1; CTRP2 3.2865 4.7883 3.2627 18.4533
HCC2279 CTRP2 3.2918 5.3282 3.2013 18.6469
NCI-H2135 GDSC1 3.2934 4.8881 2.288 4.6382
DMS 53 CTRP2 3.302 4.3365 3.2993 18.2793
NCI-H2141 GDSC1 3.3132 4.6796 2.4048 3.6743
EKVX GDSC1; CTRP2 3.3273 5.0557 3.2791 18.2649
SHP-77 GDSC1; CTRP2 3.3485 3.9813 3.3484 17.9606
NCI-H1876 GDSC1 3.353 5.306 2.1263 5.712
NCI-H1838 GDSC1; CTRP2 3.3576 4.725 3.3413 17.9545
NCI-H1836 GDSC1 3.3939 5.4829 2.0696 6.0267
NCI-H1770 GDSC1 3.4031 7.1713 1.24 12.3287
Calu-3 CTRP2 3.4248 4.7471 3.4095 17.5036
HARA [Human squamous cell lung carcinoma] CTRP2 3.4455 4.9524 3.4152 17.4165
VMRC-LCD CTRP2 3.4608 5.4968 3.3533 17.5806
NCI-H1155 GDSC1; CTRP2 3.4669 4.3115 3.4659 17.175
HCC1171 CTRP2 3.4673 8.2625 2.4225 21.0131
NCI-H2081 GDSC1; CTRP2 3.4762 4.5205 3.4719 17.1242
BEN CTRP2 3.504 3.9241 3.504 16.9241
NCI-H1395 CTRP2 3.5923 5.781 3.4354 16.8796
NCI-H510A GDSC1 3.5977 7.6179 1.1683 12.2139
HCC2935 CTRP2 3.6175 4.5955 3.6137 16.181
NCI-H661 CTRP2 3.6196 6.37 3.3025 17.2769
NCI-H441 CTRP2 3.6376 6.3368 3.3324 17.1138
NCI-H2172 CTRP2 3.6471 6.3881 3.3268 17.1059
HCC827 CTRP2 3.6649 7.4671 2.9568 18.4431
NCI-H345 GDSC1 3.6661 4.5851 2.6696 0.9681
NCI-H196 CTRP2 3.6723 9.0657 2.2834 20.981
RERF-LC-MS CTRP2 3.677 6.4337 3.3449 16.9508
IST-SL2 GDSC1 3.6792 8.0629 1.0099 13.0813
RERF-LC-Ad1 CTRP2 3.6819 4.7624 3.674 15.7657
Sq-1 CTRP2 3.6866 5.1681 3.647 15.8419
NCI-H187 GDSC1 3.6918 5.286 2.3692 2.9567
MOR/CPR CTRP2 3.6923 4.6423 3.6886 15.6824
Lu-65 GDSC1; CTRP2 3.6961 5.7271 3.5607 16.1122
IA-LM GDSC1; CTRP2 3.783 5.6974 3.6619 15.4832
NCI-H2023 CTRP2 3.8597 5.3957 3.8008 14.7551
NCI-H2171 GDSC1 3.8667 6.0916 2.103 4.4802
COR-L88 GDSC1; CTRP2 3.8857 5.8505 3.7386 14.8918
HCC366 CTRP2 3.919 5.5355 3.8414 14.425
NCI-H524 GDSC1 3.9599 5.9526 2.2263 3.3765
NCI-H2030 CTRP2 3.9635 5.8908 3.8134 14.3846
NCI-H1650 GDSC1; CTRP2 4.0085 5.8586 3.8704 14.042
NCI-H64 GDSC1 4.0645 5.6462 2.4233 1.8475
NCI-H720 GDSC1 4.0729 5.7656 2.3758 2.1364
Calu-6 GDSC1; CTRP2 4.0821 5.1698 4.0637 13.1349
NCI-H1092 GDSC1 4.1404 8.0256 1.3624 9.1977
NCI-H1869 GDSC1; CTRP2 4.1547 7.8283 3.3216 15.7022
NCI-H889 CTRP2 4.1592 5.7787 4.053 12.9258
NCI-H1793 CTRP2 4.1974 6.6578 3.8333 13.6159
HCC33 GDSC1 4.2143 8.4799 1.1942 10.1892
Lu-165 GDSC1 4.2738 6.0234 2.3715 1.831
HCC1438 CTRP2 4.2991 5.6656 4.2281 11.8709
RERF-LC-Ad2 CTRP2 4.3129 6.9393 3.8526 13.2154
NCI-H2122 CTRP2 4.3277 5.751 4.2421 11.7315
Calu-1 CTRP2 4.3354 7.7439 3.5449 14.3486
NCI-H2126 CTRP2 4.362 5.4131 4.3344 11.3013
HCC78 CTRP2 4.3681 5.3051 4.3517 11.2227
NCI-H2342 CTRP2 4.383 6.9924 3.9065 12.8138
ChaGo-K-1 CTRP2 4.4334 6.3779 4.185 11.618
NCI-H1299 CTRP2 4.4548 8.0985 3.5108 14.173
LC-1/sq-SF CTRP2 4.456 5.1506 4.4519 10.5957
COR-L105 CTRP2 4.5093 6.8098 4.1119 11.6759
NCI-H1651 CTRP2 4.5425 8.562 3.3877 14.4425
Lu-139 GDSC1 4.548 6.4263 2.3403 1.6183
NCI-H1339 CTRP2 4.5958 6.6031 4.2822 10.7844
HCC1195 CTRP2 4.5968 8.7737 3.343 14.4868
LCLC-103H CTRP2 4.6361 5.4509 4.6198 9.4372
NCI-H322M GDSC1 4.6402 9.1128 1.1787 9.1748
HCC4006 CTRP2 4.6477 5.5418 4.6222 9.3913
NCI-H460 CTRP2 4.6756 5.1759 4.6745 9.1227
KNS-62 CTRP2 4.6787 6.9935 4.219 10.7952
NCI-H322 CTRP2 4.6928 6.29 4.4956 9.7058
NCI-H226 GDSC1; CTRP2 4.7644 6.7965 4.3887 9.9054
Lu-134-A GDSC1 4.7659 9.4214 1.1148 9.2945
NCI-H1963 GDSC1 4.7798 6.9405 2.241 1.8626
NCI-H2170 CTRP2 4.9182 6.7099 4.5862 8.7208
NCI-H748 GDSC1 5.0604 7.4328 2.1743 1.8656
NCI-H1436 GDSC1 5.2527 6.9327 2.4502 0.4893
SBC-5 CTRP2 5.5113 6.0159 5.4701 3.6949
SBC-1 GDSC1 5.6086 7.1039 2.521 0.1821
NCI-H2286 CTRP2 7.3418 15.1341 2.5303 12.2114
NCI-H128 GDSC1 7.3893 16.0623 -0.337 11.9371
Hs 888.Lu CTRP2 2.5602 5.1177 2.4491 23.5907
⏷ Show the Full List of 171 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 3.6942 10.6254 -0.2508 20.8025
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 0.7374 6.153 0.2227 36.8427
COV434 CTRP2 1.2672 4.0628 1.209 32.0198
A2780 CTRP2 1.9639 4.0915 1.9357 27.2793
FU-OV-1 CTRP2 2.1075 8.2185 1.0066 29.9135
IGROV-1 CTRP2 2.2844 5.7185 2.0252 25.9408
JHOS-2 CTRP2 2.3318 3.2254 2.3317 24.7343
OV7 CTRP2 2.3966 3.6202 2.395 24.3077
COV644 CTRP2 2.4637 3.0784 2.4637 23.855
COV362 CTRP2 2.4826 4.7252 2.4222 23.9331
OVTOKO CTRP2 2.5309 4.7216 2.4738 23.6004
OAW42 CTRP2 2.5357 4.3779 2.5105 23.4599
OVCAR-5 CTRP2 2.6403 6.4402 2.2142 24.1714
OAW28 CTRP2 2.6991 4.6271 2.6611 22.4148
RMG-I CTRP2 2.7242 4.6154 2.6886 22.2393
SNU-119 CTRP2 2.8206 5.1778 2.7193 21.8226
ES-2 GDSC1 2.8329 4.7082 2.003 8.4889
Caov-3 CTRP2 2.8402 5.5935 2.6596 21.9695
TYK-nu CTRP2 2.9965 4.7689 2.9605 20.4267
SK-OV-3 CTRP2 3.0654 5.8475 2.8449 20.6124
SNU-840 CTRP2 3.2574 5.7876 3.069 19.2204
OVCAR-4 GDSC1; CTRP2 3.3247 5.5759 3.1898 18.5832
SNU-8 CTRP2 3.3291 3.9204 3.3291 18.0895
MCAS CTRP2 3.3415 5.0141 3.299 18.1504
OC 314 CTRP2 3.351 3.9668 3.3509 17.9442
HEY A8 CTRP2 3.4144 4.9528 3.3825 17.6289
TOV-21G CTRP2 3.5775 4.6165 3.5724 16.4516
ONCO-DG-1 CTRP2 3.5852 4.3659 3.5845 16.3859
OVCAR-8 CTRP2 3.6647 5.0773 3.6338 15.958
OVK18 CTRP2 3.9122 4.7946 3.9083 14.218
Kuramochi GDSC1; CTRP2 3.9685 5.701 3.8625 14.1948
OV-90 CTRP2 4.0482 5.4465 3.9952 13.4792
OVISE CTRP2 4.2401 5.4616 4.1984 12.1619
ES2 CTRP2 4.2431 5.9416 4.1056 12.4788
OVSAHO CTRP2 4.2665 5.2598 4.2491 11.9033
DOV13 CTRP2 4.2753 6.061 4.1091 12.3678
OV56 CTRP2 4.3842 5.6619 4.3209 11.2771
JHOM-1 CTRP2 4.4091 6.0173 4.2671 11.3906
EFO-21 CTRP2 4.8893 6.787 4.5248 9.0368
TOV-112D CTRP2 5.3394 6.2423 5.2131 5.1497
JHOC-5 CTRP2 6.7914 13.7338 2.8031 12.106
EFO-27 CTRP2 8.8724 23.4683 -0.4377 19.3307
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 2.6826 4.2612 2.6694 22.4412
H-STS CTRP2 2.7432 3.1974 2.7432 21.993
P-STS CTRP2 3.0971 4.6096 3.0783 19.6983
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 3.0458 5.3611 2.93 20.3731
Aska-SS CTRP2 3.3189 4.7207 3.3014 18.2164
A-204 CTRP2 -3.142 3.8949 -3.4865 59.1709
G-402 CTRP2 -1.0963 3.8121 -1.2719 47.7359
Rh41 CTRP2 0.8022 2.4912 0.8005 34.9301
SW982 GDSC1; CTRP2 2.0754 3.714 2.0682 26.4659
G-401 CTRP2 2.1529 3.5098 2.1507 25.9331
TE 617.T CTRP2 2.1875 3.4146 2.1864 25.6991
Hs 729.T CTRP2 2.2365 3.6309 2.2334 25.3789
TE 441.T GDSC1; CTRP2 2.3364 3.1049 2.3364 24.7031
RD CTRP2 2.3547 3.164 2.3546 24.5817
Tm87-16 CTRP2 2.3728 3.3974 2.3724 24.4622
Rh18 CTRP2 2.4012 4.0031 2.3914 24.3041
HT-1080 CTRP2 2.5114 2.9788 2.5114 23.5373
BT-16 CTRP2 2.7176 3.993 2.7138 22.1762
MES-SA CTRP2 2.7355 3.345 2.7355 22.0446
SW872 GDSC1 2.7414 9.4986 -0.4672 25.3129
GCT CTRP2 2.7555 4.1872 2.7472 21.9388
TTC-709 CTRP2 2.7725 4.103 2.7671 21.8158
VA-ES-BJ GDSC1 2.7984 4.3372 2.1567 7.4186
SK-LMS-1 GDSC1; CTRP2 3.2307 5.4433 3.1145 19.1436
KYM-1 CTRP2 3.3472 4.0563 3.3471 17.9696
MFH-ino GDSC1 3.3756 4.8526 2.365 3.8006
BT-12 CTRP2 3.5333 3.8452 3.5333 16.7295
EW-8 GDSC1 4.245 5.6691 2.5049 1.1075
SW684 GDSC1 4.3953 5.6452 2.5817 0.587
RKN CTRP2 4.5616 5.0182 4.5613 9.8795
SK-UT-1 GDSC1; CTRP2 5.1 6.646 4.8042 7.38
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 5.3986 6.3687 5.2305 4.9151
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; CTRP2 2.3413 5.772 2.0741 25.5913
NCI-H2452 CTRP2 2.7868 4.4186 2.7685 21.7638
MPP 89 GDSC1; CTRP2 2.845 3.8305 2.8443 21.3172
IST-Mes1 GDSC1; CTRP2 2.9204 4.4407 2.9054 20.8627
NCI-H2052 CTRP2 3.0758 6.834 2.5592 21.6176
NCI-H28 CTRP2 3.131 4.8607 3.0931 19.5373
ACC-MESO-1 CTRP2 3.5215 6.8369 3.0401 18.5362
JL-1 CTRP2 4.9313 8.1454 3.9661 11.1511
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VCaP GDSC1; CTRP2 2.3488 3.5366 2.3476 24.6244
DU145 CTRP2 4.1382 7.6904 3.3632 15.5841
LNCaP clone FGC GDSC1; CTRP2 4.2154 6.201 4.0035 12.9323
PaCa-3 CTRP2 7.0629 12.6457 3.5493 8.6476
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 1.112 3.5192 1.0879 32.9403
A-253 GDSC1; CTRP2 4.8611 6.1834 4.7125 8.4089
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 2.2971 3.5376 2.0403 10.5721
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-39 GDSC1 1.1248 3.3421 0.8509 25.2388
SNU-16 GDSC1; CTRP2 1.2167 3.2916 1.2054 32.2007
LMSU CTRP2 1.2251 5.5437 0.9128 33.1153
HGC-27 CTRP2 1.285 4.2251 1.2107 31.9546
OCUM-1 CTRP2 1.691 3.8033 1.6705 29.0715
ECC10 CTRP2 1.7003 3.2622 1.6971 28.9516
KATO III CTRP2 1.8755 5.6778 1.5894 28.744
SNU-668 CTRP2 1.9165 4.8131 1.8062 27.8735
Fu97 CTRP2 1.984 3.4517 1.981 27.061
SNU-1 GDSC1; CTRP2 2.1916 3.722 2.1862 25.6859
GSS CTRP2 2.3433 3.3416 2.343 24.6582
NCI-N87 CTRP2 2.3511 4.9321 2.254 24.9349
IM95 CTRP2 2.4978 4.2791 2.4777 23.6954
Hs 746.T CTRP2 2.5887 3.0407 2.5887 23.0224
RF-48 GDSC1 2.6527 7.2568 0.5757 19.7449
KE-39 CTRP2 2.8507 5.5559 2.6793 21.8671
SNU-216 CTRP2 2.8667 5.5115 2.7061 21.7223
HuG1-N CTRP2 3.1212 4.705 3.0967 19.5572
SNU-719 CTRP2 3.2627 5.7223 3.0901 19.1289
GSU CTRP2 3.3545 3.8648 3.3545 17.9204
23132/87 CTRP2 3.3583 4.0512 3.3582 17.8953
SNU-620 CTRP2 3.3607 5.2685 3.2851 18.1363
SNU-601 CTRP2 3.365 4.9855 3.327 17.9786
NUGC-3 CTRP2 3.3689 4.6766 3.3558 17.8684
MKN74 CTRP2 3.4634 6.0134 3.2361 17.9888
NUGC-4 CTRP2 3.5282 4.6421 3.5211 16.7869
SCH GDSC1 3.7944 6.8003 1.7143 7.5711
MKN1 CTRP2 4.509 5.1359 4.5064 10.2379
ECC12 CTRP2 4.5136 5.7413 4.4457 10.4312
AGS CTRP2 4.5355 5.5396 4.503 10.1625
GCIY GDSC1 4.5638 6.1094 2.4753 0.9038
MKN7 CTRP2 4.6861 6.2768 4.4927 9.7362
SNU-5 GDSC1 5.2696 7.0067 2.4299 0.5446
MKN45 CTRP2 5.6239 5.9751 5.6024 2.8755
SH-10-TC CTRP2 8.1576 16.444 2.4831 11.0829
SNU-685 CTRP2 2.9316 4.4411 2.9169 20.7873
SNG-M CTRP2 3.4416 5.1948 3.3827 17.54
SNU-1077 CTRP2 3.5933 5.6146 3.4734 16.742
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 -1.5713 6.9314 -2.5249 50.5515
CGTH-W-1 GDSC1; CTRP2 -1.0957 8.8538 -2.6621 48.3476
ML-1 [Human leukemia] CTRP2 2.0224 5.191 1.8551 27.3639
FTC-238 CTRP2 2.273 2.8138 2.273 25.1253
TT CTRP2 2.3708 5.1813 2.2336 24.942
BHT-101 CTRP2 2.4678 3.4729 2.4674 23.829
8305C CTRP2 2.7007 4.1747 2.6916 22.3064
TT2609-C02 CTRP2 2.7318 5.1671 2.6255 22.4314
8505C CTRP2 2.7461 4.9471 2.6743 22.2169
CAL-62 CTRP2 2.9652 4.1527 2.9616 20.5259
K5 GDSC1 3.2 7.4209 0.954 15.0928
B-CPAP CTRP2 3.2234 7.3963 2.514 21.3555
FTC-133 CTRP2 5.6291 6.2253 5.5315 3.1212
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-10B CTRP2 0.6905 3.6289 0.6425 35.8232
BB30-HNC GDSC1 1.2172 3.144 1.0132 23.6247
BB49-HNC GDSC1 1.7445 6.2468 0.2401 25.849
CAL-27 CTRP2 1.7687 3.2785 1.766 28.4945
SCC-25 CTRP2 2.131 3.841 2.1209 26.1053
SNU-46 CTRP2 2.1952 5.9834 1.8601 26.7965
BHY CTRP2 2.2064 4.8606 2.1096 25.8974
BICR 31 CTRP2 2.2183 4.0961 2.1991 25.5541
YD-8 CTRP2 2.4467 3.6033 2.4456 23.972
SNU-1076 CTRP2 2.4468 5.435 2.2662 24.5871
CAL-33 CTRP2 2.6332 5.4544 2.4645 23.3053
BICR 16 CTRP2 2.6668 5.1189 2.5635 22.8541
BICR 18 CTRP2 2.6839 4.5472 2.6523 22.4942
FaDu CTRP2 2.7056 4.8137 2.6482 22.4377
PE/CA-PJ49 CTRP2 2.7421 4.7021 2.6992 22.1449
BICR 22 CTRP2 2.7516 4.3486 2.7361 21.9887
SNU-899 CTRP2 2.9421 5.0964 2.8626 20.9381
PE/CA-PJ34 (clone C12) CTRP2 3.0537 7.9032 2.1356 23.2351
PE/CA-PJ15 CTRP2 3.1009 6.7501 2.615 21.3388
SCC-9 CTRP2 3.1929 5.8103 2.9931 19.6903
SCC-4 CTRP2 3.198 5.2398 3.1149 19.246
BICR 6 CTRP2 3.2403 5.0902 3.1821 18.8787
Detroit 562 CTRP2 3.2816 4.3611 3.2781 18.4178
HSC-4 CTRP2 3.5059 5.5331 3.3951 17.292
HSC-3 CTRP2 3.7454 5.6776 3.6252 15.7303
PE/CA-PJ41 (clone D2) CTRP2 4.2868 6.6727 3.9243 13.0169
HSC-2 CTRP2 4.3284 5.5456 4.2805 11.5951
SNU-1066 CTRP2 4.6193 7.4139 3.9806 11.8858
SCC-15 GDSC1 4.6248 14.2349 -1.3275 22.9361
SNU-1041 CTRP2 4.6693 10.4094 2.6316 17.1462
LB771-HNC GDSC1 5.1598 7.5211 2.1854 1.6886
BICR 56 CTRP2 6.6487 19.3008 -0.0872 22.1633
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JMSU-1 CTRP2 0.6853 3.2973 0.6594 35.7875
RT-112 CTRP2 1.4191 4.9425 1.2492 31.3791
U-BLC1 CTRP2 1.9867 5.0728 1.8385 27.5356
UM-UC-1 CTRP2 2.0493 4.5255 1.986 26.8295
647V CTRP2 2.2304 3.2623 2.2301 25.4105
VM-CUB-1 CTRP2 2.3671 4.6255 2.3112 24.6873
5637 CTRP2 2.6604 5.2563 2.5328 22.9805
253J CTRP2 2.7808 3.5915 2.7807 21.743
BC-3C CTRP2 2.8007 4.9863 2.7272 21.8595
SCaBER CTRP2 2.8813 5.4615 2.7323 21.5849
CAL-29 CTRP2 2.984 4.1511 2.9807 20.4
T24 CTRP2 2.9854 6.3023 2.6322 21.6212
BFTC-905 CTRP2 3.2153 4.0187 3.215 18.849
TCCSUP CTRP2 3.3191 4.5998 3.3083 18.1922
HT-1376 CTRP2 3.3654 6.7913 2.8873 19.5582
SW1710 CTRP2 3.3983 6.4978 3.0212 18.9668
J82 CTRP2 3.4077 6.6672 2.9756 19.1075
253J-BV CTRP2 3.434 4.2237 3.4335 17.3923
KU-19-19 CTRP2 3.4533 5.7348 3.2948 17.8105
RT-4 CTRP2 3.5394 5.4191 3.4525 16.9855
KMBC-2 CTRP2 3.6533 5.4416 3.5714 16.2096
639V CTRP2 4.383 4.9411 4.3823 11.0708
UM-UC-3 CTRP2 4.5579 6.9129 4.1236 11.4955
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KGN GDSC1 1.137 6.5623 -0.4999 32.7143
JAR GDSC1 1.353 4.0291 0.8452 24.0068
NT2-D1 GDSC1 2.199 3.3124 2.0243 11.1975
SW954 GDSC1 2.2315 5.126 1.2441 16.8398
LB831-BLC GDSC1 2.2421 3.182 2.1169 10.3128
NCC-IT GDSC1 2.8166 4.984 1.8513 9.7421
HeLa CTRP2 2.9757 4.1645 2.972 20.4562
SW962 GDSC1 3.1315 5.1231 2.046 7.0598
NEC8 GDSC1 3.2732 4.7395 2.3461 4.2482
OMC-1 [Human cervical carcinoma] GDSC1 3.3709 5.0424 2.269 4.5525
DSH1 GDSC1 5.278 7.3086 2.3209 0.9425
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sunitinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Sunitinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [14]
Coadministration of a Drug Treating the Disease Different from Sunitinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Metreleptin DM1NOEK Moderate Increased metabolism of Sunitinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [15]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-glulisine. Acute diabete complication [5A2Y] [16]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-aspart. Acute diabete complication [5A2Y] [17]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sunitinib and Ivosidenib. Acute myeloid leukaemia [2A60] [18]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Midostaurin. Acute myeloid leukaemia [2A60] [19]
Arn-509 DMT81LZ Major Increased metabolism of Sunitinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Gilteritinib. Acute myeloid leukaemia [2A60] [20]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Oliceridine. Acute pain [MG31] [19]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sunitinib and Dronedarone. Angina pectoris [BA40] [19]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sunitinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Levalbuterol. Asthma [CA23] [22]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Pirbuterol. Asthma [CA23] [23]
Oritavancin DM28D05 Moderate Increased metabolism of Sunitinib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Sunitinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Retigabine. Behcet disease [4A62] [19]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sunitinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [24]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Eribulin. Breast cancer [2C60-2C6Y] [19]
Tucatinib DMBESUA Moderate Decreased metabolism of Sunitinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Bosutinib. Breast cancer [2C60-2C6Y] [14]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [25]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [23]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [23]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Probucol. Coronary atherosclerosis [BA80] [19]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sunitinib and Pasireotide. Cushing syndrome [5A70] [19]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Osilodrostat. Cushing syndrome [5A70] [19]
Lumacaftor DMCLWDJ Major Increased metabolism of Sunitinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [15]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Deutetrabenazine. Dystonic disorder [8A02] [26]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Sunitinib and Ingrezza. Dystonic disorder [8A02] [27]
Cenobamate DM8KLU9 Moderate Increased metabolism of Sunitinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Fosphenytoin DMOX3LB Major Increased metabolism of Sunitinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Rufinamide DMWE60C Moderate Increased metabolism of Sunitinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Sunitinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Cannabidiol. Epileptic encephalopathy [8A62] [14]
Tazemetostat DMWP1BH Moderate Increased metabolism of Sunitinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [15]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Solifenacin. Functional bladder disorder [GC50] [19]
Boceprevir DMBSHMF Moderate Decreased metabolism of Sunitinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [19]
Telaprevir DMMRV29 Moderate Decreased metabolism of Sunitinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [28]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Sunitinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Sunitinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Etravirine DMGV8QU Moderate Increased metabolism of Sunitinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [19]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sunitinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [30]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Sunitinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [19]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sunitinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [31]
Lesinurad DMUR64T Moderate Increased metabolism of Sunitinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [15]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Sunitinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [32]
Amobarbital DM0GQ8N Moderate Increased metabolism of Sunitinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [14]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Phenolphthalein. Irritable bowel syndrome [DD91] [19]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Sunitinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [15]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sunitinib and Crizotinib. Lung cancer [2C25] [33]
Brigatinib DM7W94S Moderate Increased metabolism of Sunitinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sunitinib and Ceritinib. Lung cancer [2C25] [19]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sunitinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sunitinib and Osimertinib. Lung cancer [2C25] [34]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sunitinib and Selpercatinib. Lung cancer [2C25] [14]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Sunitinib and Lumefantrine. Malaria [1F40-1F45] [15]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sunitinib and Hydroxychloroquine. Malaria [1F40-1F45] [35]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [14]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Idelalisib. Mature B-cell leukaemia [2A82] [36]
IPI-145 DMWA24P Moderate Decreased metabolism of Sunitinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sunitinib and Vemurafenib. Melanoma [2C30] [19]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and LGX818. Melanoma [2C30] [38]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Sunitinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [15]
Exjade DMHPRWG Moderate Increased metabolism of Sunitinib caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [15]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sunitinib and Panobinostat. Multiple myeloma [2A83] [39]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Siponimod. Multiple sclerosis [8A40] [15]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Fingolimod. Multiple sclerosis [8A40] [19]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Ozanimod. Multiple sclerosis [8A40] [40]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Romidepsin. Mycosis fungoides [2B01] [19]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Sunitinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [14]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sunitinib and Nilotinib. Myeloproliferative neoplasm [2A20] [19]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Lofexidine. Opioid use disorder [6C43] [19]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Rucaparib. Ovarian cancer [2C73] [19]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Triclabendazole. Parasitic worm infestation [1F90] [19]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Pimavanserin. Parkinsonism [8A00] [41]
Abametapir DM2RX0I Moderate Decreased metabolism of Sunitinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [42]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sunitinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [43]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sunitinib and Lefamulin. Pneumonia [CA40] [44]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Sunitinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [15]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Degarelix. Prostate cancer [2C82] [14]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Sunitinib and ABIRATERONE. Prostate cancer [2C82] [14]
Enzalutamide DMGL19D Major Increased metabolism of Sunitinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [15]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Relugolix. Prostate cancer [2C82] [14]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sunitinib and Iloperidone. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sunitinib and Amisulpride. Schizophrenia [6A20] [45]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Asenapine. Schizophrenia [6A20] [19]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Sunitinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [15]
Larotrectinib DM26CQR Moderate Decreased metabolism of Sunitinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [14]
Armodafinil DMGB035 Moderate Increased metabolism of Sunitinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sunitinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [19]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Sunitinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [19]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [14]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Pitolisant. Somnolence [MG42] [19]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [19]
Fostamatinib DM6AUHV Moderate Decreased clearance of Sunitinib due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [46]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Lenvatinib. Thyroid cancer [2D10] [19]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Sunitinib and Cabozantinib. Thyroid cancer [2D10] [14]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [16]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin degludec. Type-1/2 diabete [5A10-5A11] [16]
Elagolix DMB2C0E Moderate Increased metabolism of Sunitinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [15]
⏷ Show the Full List of 108 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sunitinib 25 mg capsule 25 mg Oral Capsule Oral
Sunitinib 37.5 mg capsule 37.5 mg Oral Capsule Oral
Sunitinib 50 mg capsule 50 mg Oral Capsule Oral
Sunitinib 12.5 mg capsule 12.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Sunitinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J. 2017 Jan;17(1):42-46. doi: 10.1038/tpj.2015.100. Epub 2016 Jan 26.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
8 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
9 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
10 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
11 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
12 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
13 Drug Interactions Flockhart Table
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Cerner Multum, Inc. "Australian Product Information.".
16 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
17 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
18 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
19 Canadian Pharmacists Association.
20 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
21 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
27 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
28 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
29 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
31 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
32 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
33 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
36 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
37 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
38 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
39 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
40 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
41 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
42 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
44 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
45 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
46 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.